Harnessing inflammatory monocytes to overcome resistance to anti-PD-1 immunotherapy
Abstract Background Resistance to immune checkpoint inhibitors (ICIs) represents a major therapeutic challenge, as less than 50% of melanoma patients achieve long-term responses to ICIs. One mechanism of acquired resistance involves loss of genes required for antigen presentation, such as beta-2 microglobulin (B2m), th...